Tanja Frey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tanja Frey has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Sandra Dobs
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD 21205
1 shared publication - Agustí Rodríguez-Palmero
Paediatric Neurology Unit, Department of Pediatrics, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain
1 shared publication - Alexander Schulz
Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany
1 shared publication - Alexandra Montavont
Department of Functional Neurology and Epileptology Hospices Civils de Lyon (Lyon University Hospital), Hospital for Neurology and Neurosurgery Pierre Wertheimer Lyon France
1 shared publication - Alyssa L. Rippert
Division of Human Genetics Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
1 shared publication - Andreas Meyer-Heim
Swiss Children’s Rehab, Affoltern Am Albis, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Heterozygous Variants in LRP1 Cause a Neurodevelopmental Disorder With Congenital Heart Defects
LRP1 encodes the low‐density lipoprotein (LDL) receptor‐related protein 1 (LRP1), a transmembrane protein involved in endocytosis and activation of multiple signaling pathways. LRP1 variants have been implicated in the pathogenesis of congenital heart defects (CHD), Alzheimer's disease, and neurodevelopmental disorders (NDD). Biallelic LRP1 variants have also been reported in two siblings with CHD, hypotonia, dysmorphology, corneal clouding, and ascites. However, conclusive evidence supporting the role of LRP1 in human disease is still lacking. Individuals with heterozygous variants in LRP1 (NM_002332.3) were identified through genetic testing. GeneMatcher facilitated identification of participants and international collaboration. Comprehensive clinical and genotypic data were collected. Fifteen participants with heterozygous predicted loss‐of‐function (pLOF) or missense variants in LRP1 were identified. The most common phenotypes include NDD, CHD, musculoskeletal and gastrointestinal issues, and dysmorphic features. CHD was more common in participants with pLOF variants. Our findings suggest that LRP1 haploinsufficiency is associated with a syndromic NDD. Phenotypic differences in cardiac and neurologic involvement between participants with pLOF and missense variants suggest the possibility of alternate disease mechanisms.
- 26 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Open AccessHeterozygous Variants in LRP1 Cause a Neurodevelopmental Disorder With Congenital Heart Defects
LRP1 encodes the low‐density lipoprotein (LDL) receptor‐related protein 1 (LRP1), a transmembrane protein involved in endocytosis and activation of multiple signaling pathways. LRP1 variants have been implicated in the pathogenesis of congenital heart defects (CHD), Alzheimer's disease, and neurodevelopmental disorders (NDD). Biallelic LRP1 variants have also been reported in two siblings with CHD, hypotonia, dysmorphology, corneal clouding, and ascites. However, conclusive evidence supporting the role of LRP1 in human disease is still lacking. Individuals with heterozygous variants in LRP1 (NM_002332.3) were identified through genetic testing. GeneMatcher facilitated identification of participants and international collaboration. Comprehensive clinical and genotypic data were collected. Fifteen participants with heterozygous predicted loss‐of‐function (pLOF) or missense variants in LRP1 were identified. The most common phenotypes include NDD, CHD, musculoskeletal and gastrointestinal issues, and dysmorphic features. CHD was more common in participants with pLOF variants. Our findings suggest that LRP1 haploinsufficiency is associated with a syndromic NDD. Phenotypic differences in cardiac and neurologic involvement between participants with pLOF and missense variants suggest the possibility of alternate disease mechanisms.
- 12 May 2026
- Published by EIZ Publishing
Rare Diseases
Was sind Seltene Krankheiten? Auf diese und viele weitere Fragen zur rechtlichen, ethischen und medizinischen Beurteilung von seltenen Krankheiten gibt der Sammelband Antworten aus Wissenschaft und Praxis. Er fördert gerade auch das Verständnis juristischer Rahmenbedingungen bei der Diagnose und Therapie sowie dem medizinischen Alltag in Bezug auf Seltene Krankheiten, zeigt die Perspektiven von Betroffenen auf, erläutert nationale Bestrebungen. Der Sammelband gibt Einblicke in eine komplexe Welt, die bislang im öffentlichen Diskurs noch zu wenig Beachtung gefunden hat. Er ist ein wichtiges Werk für Medizinal- und Gesundheitsfachpersonen, Juristinnen und Juristen, Verbände, Ethikkommissionen, Politik, Patientenvertretungen, Vertretungen der Kranken- und Invalidenversicherung, Industrie und alle, die sich mit Seltenen Krankheiten befassen. Die Beiträge sind im Rahmen des Zertifikatsstudiengangs «CAS Rare Diseases» der Universität Zürich entstanden. Der Weiterbildungsstudiengang dient u.a. als Plattform für Seltene Krankheiten, fördert den fundierten Austausch zwischen Fachpersonen und vermittelt den Teilnehmenden aus einer interdisziplinären Sichtweise Wissen nach dem aktuellsten Stand.
- 12 May 2026
- Published by EIZ Publishing
Rare Diseases
Was sind Seltene Krankheiten? Auf diese und viele weitere Fragen zur rechtlichen, ethischen und medizinischen Beurteilung von seltenen Krankheiten gibt der Sammelband Antworten aus Wissenschaft und Praxis. Er fördert gerade auch das Verständnis juristischer Rahmenbedingungen bei der Diagnose und Therapie sowie dem medizinischen Alltag in Bezug auf Seltene Krankheiten, zeigt die Perspektiven von Betroffenen auf, erläutert nationale Bestrebungen. Der Sammelband gibt Einblicke in eine komplexe Welt, die bislang im öffentlichen Diskurs noch zu wenig Beachtung gefunden hat. Er ist ein wichtiges Werk für Medizinal- und Gesundheitsfachpersonen, Juristinnen und Juristen, Verbände, Ethikkommissionen, Politik, Patientenvertretungen, Vertretungen der Kranken- und Invalidenversicherung, Industrie und alle, die sich mit Seltenen Krankheiten befassen. Die Beiträge sind im Rahmen des Zertifikatsstudiengangs «CAS Rare Diseases» der Universität Zürich entstanden. Der Weiterbildungsstudiengang dient u.a. als Plattform für Seltene Krankheiten, fördert den fundierten Austausch zwischen Fachpersonen und vermittelt den Teilnehmenden aus einer interdisziplinären Sichtweise Wissen nach dem aktuellsten Stand.
- Open Access
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (4) , e200168
Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (4) , e200168
Open AccessExpanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.
- Open Access
- 4 July 2023
- Published by Taylor & Francis in Developmental Neurorehabilitation
- Vol. 26 (5) , 328-337
Perspectives of Swiss Paediatric Health Care Professionals on Factors Influencing Physical Activity Participation in Children with Disabilities
AimInvestigation of the perspectives of paediatric health care professionals (PHCPs) in Switzerland regarding factors that influence participation in physical activity programs for children and adolescents with disabilities or chronic conditions (CADCCs). Evaluation of self-reported exercise counselling behavior of those professionals.MethodA cross-sectional survey was used to collect the opinions of 171 PHCPs working with CADCCs using a structured questionnaire. The information obtained was evaluated by performing a combined quantitative and qualitative statistical analysis.ResultsPHCPs in Switzerland think that CADCC do not get enough physical activity and see the underlying reasons in lacking information/knowledge and organizational factors. We found that the level of knowledge about disability sports opportunities among PHCPs has a positive influence on their exercise counselling behaviour.ConclusionsWe propose three approaches to increase the level of physical activity in CADCC: Establishing personalized exercise counseling, intensifying information about disability sports programmes towards PHCPs, and improving inclusion and integration in PE lessons or regular sports clubs.
- 4 July 2023
- Published by Taylor & Francis in Developmental Neurorehabilitation
- Vol. 26 (5) , 328-337
Open AccessPerspectives of Swiss Paediatric Health Care Professionals on Factors Influencing Physical Activity Participation in Children with Disabilities
AimInvestigation of the perspectives of paediatric health care professionals (PHCPs) in Switzerland regarding factors that influence participation in physical activity programs for children and adolescents with disabilities or chronic conditions (CADCCs). Evaluation of self-reported exercise counselling behavior of those professionals.MethodA cross-sectional survey was used to collect the opinions of 171 PHCPs working with CADCCs using a structured questionnaire. The information obtained was evaluated by performing a combined quantitative and qualitative statistical analysis.ResultsPHCPs in Switzerland think that CADCC do not get enough physical activity and see the underlying reasons in lacking information/knowledge and organizational factors. We found that the level of knowledge about disability sports opportunities among PHCPs has a positive influence on their exercise counselling behaviour.ConclusionsWe propose three approaches to increase the level of physical activity in CADCC: Establishing personalized exercise counseling, intensifying information about disability sports programmes towards PHCPs, and improving inclusion and integration in PE lessons or regular sports clubs.
- 24 November 2017
- Published by Springer Nature in Cancer Causes & Control
- Vol. 29 (1) , 157-166
Consumption of caffeinated beverages and serum concentrations of sex steroid hormones in US men
By modulating the levels of sex steroid hormones and sex hormone-binding globulin (SHBG), caffeine could be a factor in the development of several conditions in men, including prostate cancer. The aim of this study was to evaluate if caffeine consumption is associated with concentrations of sex steroid hormones and SHBG in men.
- 24 November 2017
- Published by Springer Nature in Cancer Causes & Control
- Vol. 29 (1) , 157-166
Consumption of caffeinated beverages and serum concentrations of sex steroid hormones in US men
By modulating the levels of sex steroid hormones and sex hormone-binding globulin (SHBG), caffeine could be a factor in the development of several conditions in men, including prostate cancer. The aim of this study was to evaluate if caffeine consumption is associated with concentrations of sex steroid hormones and SHBG in men.